Metformin reverses hexokinase and phosphofructokinase downregulation and intracellular distribution in the heart of diabetic mice.
Diabetes mellitus is characterized by hyperglycemia and its associated complications, including cardiomyopathy. Metformin, in addition to lowering blood glucose levels, provides cardioprotection for diabetic subjects. Glycolysis is essential to cardiac metabolism and its reduction may contribute to diabetic cardiomyopathy. Hexokinase (HK) and phosphofructokinase (PFK), rate-limiting enzymes of glycolysis, are downregulated in cardiac muscle from diabetic subjects, playing a central role on the decreased glucose utilization in the heart of diabetic subjects. Thus, the aim of this study was to determine whether metformin modulates heart HK and PFK from diabetic mice. Diabetes was induced by streptozotocin injection on male Swiss mice, which were treated for three consecutive days with 250 mg/kg metformin before evaluating HK and PFK activity, expression, and intracellular distribution on the heart of these subjects. We show that metformin abrogates the downregulation of HK and PFK in the heart of streptozotocin-induced diabetic mice. This effect is not correlated to alteration on the enzymes' transcription and expression. However, the intracellular distribution of both enzymes is altered in diabetic hearts that show increased activity of the soluble fraction when compared to the particulate fraction. Moreover, this pattern is reversed upon the treatment with metformin, which is correlated with the effects of the drug on the enzymes activity. Altogether, our results support evidences that metformin alter the intracellular localization of HK and PFK augmenting glucose utilization by diabetic hearts and, thus, conferring cardiac protection to diabetic subjects.
Laboratório de Enzimologia e Controle do Metabolismo-LabECoM, Faculdade de Farmácia, UFRJ, Brazil.
Daniel
D
Da Silva
Priscila
P
Ausina
Edgard M
EM
Alencar
Wagner S
WS
Coelho
Patricia
P
Zancan
Mauro
M
Sola-Penna
D000818:Animals; D001786:Blood Glucose; D002316:Cardiotonic Agents / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000188:drug therapy / Q000201:enzymology; D058065:Diabetic Cardiomyopathies / Q000188:drug therapy* / Q000201:enzymology; D015536:Down-Regulation / Q000187:drug effects*; D006593:Hexokinase / Q000235:genetics / Q000378:metabolism*; D007424:Intracellular Fluid / Q000201:enzymology; D008297:Male; D008687:Metformin / Q000494:pharmacology*; D051379:Mice; D009206:Myocardium / Q000201:enzymology*; D025221:Phosphofructokinases / Q000235:genetics / Q000378:metabolism*; D014158:Transcription, Genetic / Q000187:drug effects
D001786:Blood Glucose; D002316:Cardiotonic Agents; D008687:Metformin; D025221:Phosphofructokinases; C515658:HK1 protein, mouse; D006593:Hexokinase